Favorable outcomes and reduced toxicity with a novel vinblastine-based non-high dose methotrexate (HDMTX) regimen (modified MCP-842) in pediatric anaplastic large cell lymphoma (ALCL): experience from India (Record no. 84238)

000 -LEADER
fixed length control field 02181nab a22003137a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 191130b2019 xxu||||| |||| 00| 0 eng d
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Vijayasekharan K
245 ## - TITLE STATEMENT
Title Favorable outcomes and reduced toxicity with a novel vinblastine-based non-high dose methotrexate (HDMTX) regimen (modified MCP-842) in pediatric anaplastic large cell lymphoma (ALCL): experience from India
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT)
Date of publication, distribution, etc 2020
300 ## - PHYSICAL DESCRIPTION
Extent
500 ## - GENERAL NOTE
General note Address for Corresponding Author: drgauravnarula@gmail.com
520 ## - SUMMARY, ETC.
Summary, etc Anaplastic large cell lymphoma (ALCL) is a rare form of non-Hodgkin lymphoma (NHL) in children. Most treatment regimens include high-dose methotrexate (HDMTX), which is logistically difficult to administer in resource-limited settings. We evaluated the outcomes of pediatric ALCL patients treated on a uniform protocol (Modified Multicentric Protocol, MCP-842 regimen) at our hospital between January 2005 and December 2016. Of the 68 patients who received treatment on the Modified MCP842 protocol, 46 patients are alive in remission, 11(16%) had disease progression, 9(13%) relapsed after achieving remission, and 5(7%) had treatment-related mortality (TRM). Seventeen of 20 relapsed/progressed patients subsequently expired. With a median follow-up of 55 months (range 2-165 months), the 4-year event-free survival (EFS) and overall survival (OS) are 63% (95% CI of 50-73%) and 70%(95% CI of 57-79%), respectively. An indigenous protocol using vinblastine (without HDMTX and steroids) is feasible in a resource-limited setting and achieves outcomes comparable to regimens incorporating HDMTX, with lower toxicity.
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Pediatric ALCL
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Outcomes
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name as entry element Vinblastine
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Prasad M
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Pradhan ND
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Phillip D
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Gujral S
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Shet T
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Sridhar E
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Kembhavi S
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Shah S
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Banavali SD
700 ## - ADDED ENTRY--PERSONAL NAME
Personal name Narula G
Relator term Corresponding Author
773 ## - HOST ITEM ENTRY
Main entry heading Leukemia & Lymphoma
Place, publisher, and date of publication Philadelphia, PA: Taylor & Francis, 2020
Relationship information Vol. 61, no. 4, p. 912-918.
International Standard Serial Number 1042-8194
906 ## - LOCAL DATA ELEMENT F, LDF (RLIN)
Dept Medical Oncology
Corporate name TMC
PMID 31774004
Article Type Original Article
Country type International
Added Entry TMH - HBNI
First Author TMH
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Item type Articles
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Permanent location Current location Date acquired Barcode Date last seen Koha item type
          Tata Memorial Hospital Tata Memorial Hospital 2019-11-30 AR19757 2019-11-30 Articles

Powered by Koha